Coopervision Inc 5870 Stoneridge Drivesuite 1pleasanton Ca 94588 Pma Numberp180035 Supplement Numbers012 Date Received09 30 2022 Decision Date12 07 2022 Product Code Qit Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted No

FDA Filings

This page includes the latest FDA filings for Coopervision Inc 5870 Stoneridge Drivesuite 1pleasanton Ca 94588 Pma Numberp180035 Supplement Numbers012 Date Received09 30 2022 Decision Date12 07 2022 Product Code Qit Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted No. Currently, you will find the latest 100 filings for Premarket Notifications, Premarket Applications, De Novo Applications, and GUDID registrations.

FDA Filings

Device Company	Device	Date
PMA P180035S012 CooperVision, Inc.5870 Stoneridge Drivesuite 1pleasanton, CA 94588 PMA NumberP180035 Supplement NumberS012 Date Received09/30/2022 Decision Date12/07/2022 Product Code QIT  Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted? No	MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear	2022-12-07